Watch Dr. Neha S. Korde, an assistant professor in multiple myeloma service in the Division of Hematology at Memorial Sloan Kettering Cancer Center, present on MGUS/smoldering myeloma. Multiple ...

We studied 1384 patients who were residing in southeastern Minnesota and in whom MGUS was diagnosed at the Mayo Clinic in the period from 1960 through 1994; the median follow-up was 34.1 years (range, ...

Patients with monoclonal gammopathy of undetermined significance (MGUS), a precursor to multiple myeloma (MM), can progress from low- or intermediate-risk to MM in just 5 years, according to ...

Individuals with low-risk or intermediate-risk monoclonal gammopathy of undetermined significance (MGUS) may convert to high-risk MGUS and progress to multiple myeloma within 5 years, researchers ...

To date, there are no drug therapies that have been effective in treating MGUS. German investigators found that WBV increased MGUS patients’ physical performance in 3 separate types of tests, at both ...

As a part of its “Speaking Out” video series, on behalf of the International Myeloma Foundation, CURE® spoke with their chief medical officer, Dr. Joseph Mikhael about the precursors to multiple ...

Monoclonal gammopathy of undetermined significance (MGUS) is an abnormal finding of a blood test. It means there’s a specific protein present in your blood and is an early sign of certain types of a ...

Identifying the patients most likely to progress from a precancerous condition to multiple myeloma could help doctors catch the disease early and stop it taking hold. Unlike many other forms of cancer ...

Computer-Assisted Flagging of Individuals at High Risk of Colorectal Cancer in a Large Health Maintenance Organization Using the ColonFlag Test Recent advances have uncovered therapeutic interventions ...

Moving Beyond Autologous Transplantation in Multiple Myeloma: Consolidation, Maintenance, Allogeneic Transplant, and Immune Therapy Importantly, the revised definition excluded patients previously ...